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Objective: Adenosine-to-inosine (A-to-I) RNA editing of Alu retroelements is a primate-specific mechanism
mediated by adenosine deaminases acting on RNA (ADARs) that diversifies transcriptome by changing selected
nucleotides in RNA molecules. We tested the hypothesis that A-to-I RNA editing is altered in rheumatoid arthritis
(RA).
Methods: Synovium expression analysis of ADAR1 was investigated in 152 RA patients and 50 controls.
Peripheral blood mononuclear cells derived from 14 healthy subjects and 19 patients with active RA at baseline
and after 12-week treatment were examined for ADAR1p150 and ADAR1p110 isoform expression by RT-qPCR.
RNA editing activity was analysed by AluSx+ Sanger-sequencing of cathepsin S, an extracellular matrix de-
gradation enzyme involved in antigen presentation.
Results: ADAR1 was significantly over-expressed in RA synovium regardless of disease duration. Similarly,
ADAR1p150 isoform expression was significantly increased in the blood of active RA patients. Individual nu-
cleotide analysis revealed that A-to-I RNA editing rate was also significantly increased in RA patients. Both
baseline ADAR1p150 expression and individual adenosine RNA editing rate of cathepsin S AluSx+ decreased
after treatment only in those patients with good clinical response. Upregulation of the expression and/or activity
of the RNA editing machinery were associated with a higher expression of edited Alu-enriched genes including
cathepsin S and TNF receptor-associated factors 1,2,3 and 5.
Conclusion: A previously unrecognized regulation and role of ADAR1p150-mediated A-to-I RNA editing in post-
transcriptional control in RA underpins therapeutic response and fuels inflammatory gene expression, thus re-
presenting an interesting therapeutic target.
1. Introduction
Rheumatoid Arthritis (RA) is a chronic inflammatory rheumatic
disease, which affects approximately 0.5–1% of the population world-
wide [1]. To date RA remains an incurable disease, heavily affecting the
quality of life of the patients, their ability to work, as well as their life
expectancy overall [1]. Significant advances in the understanding of
disease pathogenesis in the past decades, mainly the delineation of the
pivotal role of tumor necrosis factor alpha (TNFα), have led to the
development of biological therapies, which have transformed the
course of these patients [2]. However, in 2019 remission and drug-free
remission rates among RA patients remain unsatisfactorily low [1,3],
with more than half of the patients treated with biological therapies
showing persisting clinically active disease [4]. Moreover, there are
currently no established biomarkers that can predict response to
therapy [5]. Therefore, there is a demanding need to explore novel
aspects underlying the pathogenetic mechanisms involved in RA.
Adenosine-to-inosine (A-to-I) RNA editing is the most abundant
substitutional RNA modification, catalysed by the enzymes adenosine
deaminases acting on RNA-1 and -2 (ADAR1 and ADAR2) [6]. A-to-I
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RNA editing takes place predominantly in repetitive non-coding regions
of RNA, namely Alu elements, which have the ability to form double-
stranded RNA regions, a pre-requisite for RNA editing [7–11]. Alu RNA
editing is mainly, if not exclusively, catalysed by ADAR1 and is a
widespread phenomenon, as Alu elements account for approximately
10% of the human genome [11]. Interestingly, presence of Alu elements
in human genes has recently emerged as a critical regulator of RNA
metabolism dictating the fate of the RNA molecules including alter-
native splicing, mRNA stability and translation [10,12]. More im-
portantly, Alu elements are conserved only in primates, therefore Alu
RNA editing constitutes an additional level of gene regulation specific
for human disease [10,12,13]. Despite significant advances in the study
of RNA editing with the introduction of second-generation RNA se-
quencing, the involvement of Alu RNA editing in human disease de-
velopment and progression is currently poorly understood [12].
Herein, we tested the hypothesis that ADAR1 expression and A-to-I
RNA editing are altered in the pro-inflammatory milieu of RA, probably
influencing the expression of Alu-enriched pro-inflammatory genes. As
an example, here, we focused on cathepsin S, a well-established target
of ADAR1, whose mRNA stability and expression is controlled by Alu
RNA editing [14]. Cathepsin S has an essential role in major histo-
compatibility complex (MHC)–II–mediated antigen presentation [15],
autoantibody production [16] and extracellular matrix degradation
[17], and has been previously reported to control experimental RA
development in mouse [18], as well as to be increased in both the sy-
novial fluid [19] and the systemic circulation of patients with RA [20].
2. Materials and methods
2.1. Analysis of RNA-sequencing dataset of synovial tissues
A large RNA-sequencing dataset (GSE89408) [21] including in total
202 synovial biopsy samples (normal joint= 28, osteoarthritis = 22,
early RA-disease duration<1 year= 57, established RA=95) was
accessed through the NCBI database. Aligned data on ADAR1 and ca-
thepsin S expression were extracted through the Gene Expression Om-
nibus database.
2.2. Analysis of RNA-sequencing dataset for ADAR1p110 and ADAR1p150
isoform expression
RNA-sequencing data (read length 101 bp generated from total
RNA) from synovial samples of normal (28), osteoarthritis (22), early
rheumatoid arthritis (57) and established rheumatoid arthritis (95)
patients, were downloaded from the NCBI Sequence Read Archive
(SRP092408) in .sra format and converted in .fastq by means of fastq-
dump program that is part of the SRA toolkit package. Low-quality
reads were discarded by filtering with the NGS QC Toolkit [22] and
default parameters (cutoff read length for HQ=70%, cutoff quality
score= 20). High quality cleaned reads were mapped against pre-in-
dexed human genome GRCh37, transcriptome (pre-processed set of
known splice junctions from Ensembl annotation), and dbSNP common
release 144 using HISAT2 version 2.1.0 [23] and default parameters.
Unique and concordant alignments in .sam format were converted in
the binary .bam format, sorted by genomic coordinates, and indexed by
SAMtools. Transcriptome quantification was performed for each sample
with StringTie v1.3.6 release [24] and differential expression was tested
with the DESeq2 1.24.0 [25] (FDR≤ 0.05) R package. Reference
human transcriptome was obtained from UCSC (http://hgdownload.
cse.ucsc.edu/goldenpath/hg19/database/). Expression of ADAR1 iso-
forms, ADAR1p150 (NM_001111) and ADAR1p110 (NM_001025107),
was determined for each sample.
2.3. Patient recruitment and follow-up
Peripheral blood was collected in EDTA tubes (BD Vacutainer) from
19 consecutive consenting patients with RA fulfilling the 2010 ACR/
EULAR criteria [26] and 14 apparently healthy controls (HC). All pa-
tients had active disease (DAS28-ESR: 3.4–7.1) at the time of sampling.
Exclusion criteria included viral or bacterial infection during the past
month and severe co-morbidities (cancer, heart or kidney failure).
Clinical and laboratory RA features [28 tender/swollen joint count,
erythrocyte sedimentation rate (ESR; mm/1st h.), C-reactive protein
(CRP; mg/dl), visual analogue scale (VAS)-patient global] and rheu-
matoid factor (RF)/anti-cyclic citrullinated peptide (CCP) status were
recorded at baseline (Table 1).
RA patients were re-examined 12 weeks after initiation of new
treatment (scale-up of treatment, conventional synthetic disease-mod-
ifying antirheumatic drugs (csDMARDS) ± corticosteroids and/or
Table 1
Demographics, clinical and laboratory features of controls and RA patients at baseline and after 12-week treatment.
Rheumatoid Arthritis (n= 19) EULAR Responders (n= 11) EULAR moderate/non-responders (n= 8) Controls (n= 14)
Baseline Baseline 12 weeks Baseline 12 weeks Baseline
Men/women, n 4/15 2/9 2/6 5/9
Age (mean ± SD, years) 54.2 ± 16.0 47.9 ± 14.8 62.8 ± 14.1 39.0 ± 12.6
Disease duration (mean ± SD, years) 7.3 ± 7.4 6.0 ± 7.2 9.0 ± 7.6 n/a
Disease activity
Tender joint count (28), n 7.9 ± 5.3 7.3 ± 5.4 1.0 ± 1.8* 8.8 ± 5.5 5.4 ± 4.7* 0
Swollen joint count (28), n 5.4 ± 4.0 3.9 ± 3.8 0.8 ± 1.5* 7.5 ± 3.6 4.0 ± 3.2* 0
ESR (mm/1st h) 34 ± 23 33 ± 28 12 ± 15* 36 ± 15 26 ± 7* n/a
CRP (mg/dl) 1.7 ± 1.5 1.6 ± 1.9 0.3 ± 0.3* 1.9 ± 0.9 0.9 ± 0.6* n/a
DAS28-ESR 5.2 ± 1.2 5.0 ± 1.3 2.0 ± 0.8* 5.5 ± 1.1 4.5 ± 1.2* n/a
Auto-antibodies
RF positivity, n (%) 11 (57.9) 6 (54.5) 5 (62.5) n/a
anti-CCP positivity, n (%) 12 (63.2) 7 (63.6) 5 (62.5) n/a
Therapy
csDMARDs, n (%) 5 (26.3) 3 (27.3) 6 (54.5) 2 (25.0) 4 (50.0) 0
corticosteroids, n (%) 6 (31.6) 3 (27.3) 5 (45.5) 3 (37.5) 4 (50.0) 0
anti-TNF, n (%) 0 (0.0) 0 (0.0) 6 (54.5) 0 (0.0) 5 (62.5) 0
anti-IL-1, n (%) 0 (0.0) 0 (0.0) 2 (18.2) 0 (0.0) 0 (0.0) 0
anti-CD20, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (12.5) 0
ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; DAS: disease activity score; RF: rheumatoid factor; anti-CCP: anti-cyclic citrullinated peptide;
csDMARDS: conventional synthetic disease-modifying antirheumatic drugs(methotrexate, leflunomide); TNF: tumor necrosis factor; IL-1: interleukin 1; *P < 0.05
compared to baseline.
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biological DMARDS) and were categorized in responders and mod-
erate/non-responders according to EULAR's response criteria [27]
(treatment modalities and their effect on disease characteristics in
EULAR responders vs moderate/non-responders are shown in Table 1).
For schematic representation of study design and patient recruitment
see Supplementary Fig. 1. All participants gave written informed con-
sent in compliance with the Declaration of Helsinki, which had been
previously approved by the Ethics Committee of Laiko Hospital, Athens,
Greece (Protocol Nr.:1368/17-11-2016), as well as by the Hellenic Data
Protection Authority (Protocol Nr.:ΓΝ/ΕΞ/7901-2/22-12-2016).
2.4. Alu Sanger sequencing and RNA editing analysis
cDNA from peripheral blood mononuclear cells (PBMCs) was sub-
jected to PCR with KOD Hot-start DNA polymerase (Millipore) for the
amplification of the most edited Alu region in cathepsin S 3′ un-
translated region (UTR), namely AluSx+ (PCR product size: 442bp)
[14]. Gel-extracted PCR product was subjected to Sanger sequencing
and editing rates of individual adenosines were determined following
the analysis of the chromatopherograms as we have previously de-
scribed [14].
2.5. Statistical analysis
Statistical analysis was conducted with SPSS 24.0. Normality of
continuous variables was graphically assessed by histograms and P–P
plots, as well as by Kolmogorov-Smirnov and Shapiro-Wilk tests.
Pairwise differences were evaluated with two independent samples
Student's t-test or the non-parametric Mann-Whitney U test for con-
tinuous variables between groups of RA and controls and chi-squared
test for nominal variables. The Kruskal-Wallis test was used when
comparing more than 2 groups. In order to account for multiple com-
parisons, Bonferroni correction was performed where applicable. Linear
regression analysis was used to control for the effect of confounding
factors. Correlations between continuous variables were explored with
Pearson's test when normal distribution applied and Spearman's rank
test for non-normal variables. Changes in continuous variables fol-
lowing treatment (same patients) were examined with the use of paired
t-test or Wilcoxon signed-rank test for non-normal variables. Results
were considered statistically significant when P < 0.05.
More details on PBMC isolation, RNA extraction, gene expression
analysis, sample size calculation and patient and public involvement
are given in Supplementary methods.
3. Results
3.1. The RNA editor ADAR1 is increased in RA synovium and peripheral
blood
Expression analysis of the RNA-sequencing dataset GSE89408 re-
vealed significant upregulation of total ADAR1 in synovium of patients
with either early RA or established RA (P < 0.001 for each compar-
ison: early or established RA vs. normal synovium or osteoarthritis,
Fig. 1A). Interestingly there was a trend upregulation of ADAR1 in early
RA when compared to established RA (P=0.06 early vs. established
RA). ADAR1 has two isoforms, namely ADAR1p110 and ADAR1p150
[6,28]. ADAR1p110 is constitutively expressed [6,28], while the in-
terferon-inducible ADAR1p150 was reported to be also induced by the
pro-inflammatory cytokines TNFα and interferon-γ [14]. Expression of
ADAR1p150 isoform was significantly increased in rheumatoid syno-
vium as well as in PBMCs of active RA patients (Fig. 1B,D), while mRNA
levels of the constitutively expressed ADAR1p110 isoform did not differ
between patients and controls (Fig. 1C,E). The expression levels of the
second RNA editor ADAR2 (ADARB1) were similar in RA patients and
healthy controls (Supplementary Fig. 2) indicating that ADAR1p150 is
the only RNA editing enzyme induced under pro-inflammatory
conditions in RA patients. Taken together these results suggest that
total ADAR1 and particularly its pro-inflammatory isoform ADAR1p150
is increased in RA in both PBMCs and synovial tissue.
3.2. Increased Alu A-to-I RNA editing rate in active RA
In order to evaluate the RNA editing activity of ADAR1, we se-
quenced the AluSx+ that is located in cathepsin S mRNA 3′ UTR
(Fig. 2A), which is edited only by ADAR1 and is responsible for the
post-transcriptional regulation of cathepsin S mRNA stability and ex-
pression [14]. Since inosines are recognized by the reverse transcriptase
as guanosines, we could detect A-to-I RNA editing levels of modified
adenosines as A-to-G nucleotide mismatches when we compare the RNA
sequence with the genome. We were able to detect more than 20 edited
adenosines (Supplementary Table 1). Both the average of all edited
adenosines (P=0.02) in AluSx+ as well as the individual RNA editing
rate of 8 specific adenosines (Fig. 2B) were significantly higher in RA
compared to controls (6–47% increase per adenosine, P < 0.05 for all,
Fig. 2B). The RNA editing rates of 16 individual adenosines within
cathepsin S 3′ UTR AluSx+ strongly correlated with ADAR1p150 mRNA
levels (r= range 0.454–0.754, P≤ 0.05 for all-Supplementary Table 1)
The average RNA editing rate of the 8 significantly higher edited nu-
cleotides (depicted in Fig. 2B) correlated with the expression of the pro-
inflammatory inducible ADAR1p150 isoform (n=19, r= 0.623,
P= 0.004, Fig. 2C), but not with the constitutively expressed
ADAR1p110 isoform (r= 0.265, P=0.27).
3.3. Treatment of RA decreases A-to-I RNA editing levels only in responding
patients
Next, we investigated whether the observed upregulation of
ADAR1p150 and AluSx+ RNA editing rate in active RA was reversible
after 12 weeks of antirheumatic treatment with csDMARDS, corticos-
teroids and/or bDMARDs. Of note, both ADAR1p150 expression levels
and average AluSx+ RNA editing rate decreased post-treatment only in
EULAR responders (P=0.008 and P=0.02, respectively) (Fig. 3A and
B), while they remained unaffected in those patients with moderate to
no response (Fig. 3C and D). These results indicate that the effect of the
antirheumatic treatment on RNA editing machinery depends on the
clinical response to the given therapy, thus suggesting that the dynamic
regulation of Alu A-to-I RNA editing reflects the course of RA.
3.4. Increased A-to-I RNA editing is associated with pro-inflammatory gene
expression
A-to-I RNA editing of Alu elements disrupts the double-stranded
RNA structure through the production of weak I–U bonds, unwinding
double-stranded RNA secondary structure [10]. In this way, double-
stranded RNA is regionally converted into a more single-stranded
structure enabling the binding of single-strand RNA-binding proteins,
such as HuR (ELAVL1), which can stabilize mRNAs and, thus, increase
their expression, as we have previously described for cathepsin S mRNA
[14]. Herein, we used cathepsin S, not only as a well-established target
of ADAR1 [14] but also as an important molecule in RA development
[18] to test whether the observed upregulation of ADAR1-mediated Alu
RNA editing rate was associated with increased cathepsin S mRNA
expression in RA. First, we confirm previous reports showcasing that
cathepsin S mRNA expression was significantly increased in PBMCs of
active RA patients (1.34-fold increase compared to healthy controls,
P < 0.05, Fig. 4A), as well as at the synovium of RA patients (6-fold
increase compared to normal synovium, P < 0.001, Fig. 4B). Most
importantly, cathepsin S expression significantly correlated with the
pro-inflammatory inducible ADAR1p150 isoform (r= 0.623,
P= 0.004), as well as with the RNA editing rate of 12 individual
adenosines within cathepsin S AluSx+ (r= range 0.461–0.716,
P≤ 0.05 for all; Supplementary Table 1) and mean RNA editing rate
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(r= 0.589, P=0.008, Fig. 4C) in active RA. In contrast, no association
was observed between the constitutively expressed ADAR1p110 iso-
form and cathepsin S mRNA levels (r= 0.268, p=0.27). Next, we
studied the association between the expression of ADAR1 and cathepsin
S in a large cohort of RA synovial tissue. Interestingly, a similar cor-
relation between ADAR1 and cathepsin S mRNA was also observed in
synovial tissue derived from RA patients (n=152, r= 0.516,
P < 0.001, Fig. 4D) indicating that inflammation-induced Alu A-to-I
RNA editing may augment cathepsin S mRNA.
Since RNA editing controls cathepsin S expression through in-
creased HuR binding to AluSx+ [14], we statistically controlled for the
potential involvement of HuR in regulation of cathepsin S expression by
ADAR1p150-mediated RNA editing in RA. Towards this goal, we used a
linear regression analysis for cathepsin S mRNA expression levels (de-
pendent variable) and ADAR1p150 or average cathepsin S AluSx+ RNA
editing rate controlling for the effect of HuR expression in these sam-
ples. Indeed, controlling for HuR abolished the observed relationship
between cathepsin S mRNA expression and ADAR1p150 (P=0.58) or
average AluSx+ RNA editing (P=0.29) suggesting that regulation of
cathepsin S expression by RNA editing in RA is mainly mediated by
HuR.
Of note, cathepsin S is only an example among several Alu-enriched
Fig. 1. The RNA editing enzyme ADAR1 is increased in RA A,B,C.
Expression analysis of ADAR1 mRNA levels and of its isoforms ADAR1p110 and ADAR1p150 at synovial biopsies derived from the RNA sequencing dataset
GSE89408. The lines and P-values represent the comparison between early or established RA vs. normal synovium or osteoarthritis. D,E. mRNA expression levels of
the interferon-inducible ADAR1p150 isoform (D) and the constitutively expressed ADAR1p110 isoform (E) in PBMCs of patients with active RA (n= 19) and controls
(n=14) as determined by qPCR with specifically designed Taqman primers (ADAR1p110: Hs01017596; ADAR1p150: Hs01020780, Applied Biosystems). Expression
levels were normalized with the use of TBP as housekeeping gene (Hs00427621, Applied Biosystems). Lines in the scatter-plots represent mean ± SEM. P-values
were produced by Mann-Whitney U test. Est. RA: established rheumatoid arthritis (> 1 year disease duration); OA: osteoarthritis.
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Fig. 2. Increased Alu A-to-I RNA editing rate in active RA A.
Schematic representation of cathepsin S 3′ UTR and cDNA sequence of cathepsin S AluSx+. All detected edited adenosines are depicted in green, while individual
adenosines with significantly increased RNA editing rates in RA PBMCs are depicted in red. HuR binding sites are underlined. B. Chromatopherograms depict the
genomic sequence (upper part) and the cDNA sequence (lower part) showing the RNA editing events (A-to-G mismatches). Scatter-plots depict RNA editing rate of 8
individual adenosines in PBMCs of active RA patients (n=19) vs. healthy controls (n= 14). RNA editing rates of individual adenosines were determined following
analysis of chromatopherograms. C. Scatter-plot (left) of mean cathepsin S AluSx+ RNA editing rate of the 8 edited adenosines in PBMCs from patients with active RA
(n=19) vs. controls (n=14) and scatter-plot (right) showing correlation of individual RNA editing rates with ADAR1p150 mRNA levels in RA patients. Lines in the
scatter-plots represent mean ± SEM. P-values were produced by Mann-Whitney U test/independent-samples t-test or Spearman's rank test, respectively. (For in-
terpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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pro-inflammatory genes, which are predicted to be highly edited ac-
cording to the RNA editing database RADAR [29] and whose regulation
by RNA editing in inflammatory disease warrants further investigation.
For example, TNF receptor-associated factors TRAF1, TRAF2, TRAF3,
TRAF5 have 10–117 Alu elements and 18-1135 predicted RNA editing
sites, while when we analysed their expression in rheumatoid syno-
vium, we found a significant correlation with ADAR1 expression
(n=152, r= range 0.356–0.743, Supplementary Table 2).
Taken together, our findings imply that Alu RNA editing may be a
global primate-specific mechanism controlling Alu-enriched in-
flammatory mediators at post-transcriptional level through HuR-medi-
ated RNA processing/stability in patients with RA. The proposed me-
chanism is summarized in Fig. 5.
4. Discussion
The present study provides first evidence that: 1) the RNA editor
ADAR1, and specifically ADAR1p150 isoform, is increased in diseased
synovium, the target tissue in RA, 2) the pro-inflammatory ADAR1p150
isoform as well as the A-to-I RNA editing rates of repetitive Alu ele-
ments are increased in circulating mononuclear cells from patients with
active RA, 3) after a 12-week antirheumatic treatment reductions of
ADAR1p150 expression and Alu A-to-I RNA editing rates are prominent
only in patients with good clinical response and 4) increased Alu RNA
editing rate is associated with increased pro-inflammatory gene ex-
pression in RA.
ADAR1-mediated RNA editing is indispensable for life, as mice
lacking ADAR1 or having an editing-deficient knock-in mutation die in
utero [30–32]. In humans, mutations in ADAR1 cause Aicardi-Goutières
Syndrome associated with a type I interferon signature [33]. Further,
ADAR1 and especially its isoform ADAR1p150 is a type I interferon-
inducible gene [28]. Accordingly, ADAR1 expression was found to be
increased in type I interferon-associated autoimmune diseases [34–39],
but also in other inflammatory diseases including acute myocardial
infarction, atherosclerosis, cancer and viral infections [14,40,41]. More
importantly, ADAR1 expression and activity are increased after stimu-
lation with TNFα [14], the major cytokine that regulates the dynamics
of transcriptome in RA [42], due to a significant increase in levels of
ADAR1p150 isoform [14]. Our results may suggest that ADAR1 and
specifically the ADAR1p150 isoform is increased in RA through a sy-
nergistic effect driven by TNF and type I interferon signaling. The up-
regulation of ADAR1 was found at the inflammatory tissues as well as in
the circulation, and therefore, ADAR1 may have an impact on other
autoimmune diseases besides RA. Further studies are warranted to
elucidate the systematic and tissue- and cell-specific regulation and role
of ADAR1, and more specifically of the pro-inflammatory ADAR1p150
isoform, in systemic autoimmunity.
ADAR1-induced A-to-I RNA editing takes place primarily in re-
petitive Alu elements, therefore comprising an upstream regulatory
mechanism of RNA metabolism specific for primates [8–13]. The
widespread Alu elements have recently emerged as critical regulators of
inflammation [43] and an enrichment of Alu elements has been recently
reported in autoimmune diseases, potentially contributing to type I
interferon pathway activation [43,44]. Data in systemic autoimmune
disease are yet controversial, as studies have shown up-regulation of
global Alu RNA editing index in peripheral blood of patients with sys-
temic lupus erythematosus [38], but downregulation in keratinocytes of
patients with psoriasis [39]. Clearly, comparative studies at tran-
scriptome-wide level and especially at a single nucleotide or Alu level of
individual transcripts in inflammatory and autoimmune diseases are
Fig. 3. Effect of antirheumatic treatment on
ADAR1p150 and RNA editing is dependent on clin-
ical response.
The effect of antirheumatic treatment on
ADAR1p150 mRNA expression levels and cathepsin S
AluSx+ RNA editing rate at baseline (week 0) and
after 12-week treatment in EULAR responders
(n= 11, A,B) and moderate/non-responders (n= 8,
C,D). Individual ADAR1p150 expression levels and
RNA editing rate of cathepsin S AluSx+ were stan-
dardized to the baseline median per group to show
the effect of treatment (fold-change). Lines in the
scatter-plots represent mean ± SEM. P-values were
produced by Wilcoxon's signed-rank test or paired t-
test.
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warranted to enlighten the tissue-specific and disease-specific effects of
Alu A-to-I RNA editing. The difference between global and transcript-
specific RNA editing levels among the inflammatory and especially the
autoimmune diseases may reflect not only the tissue-specificity of RNA
editing [45], but also the inflammatory microenvironment and milieu
in each disease [46]. We found that effective anti-inflammatory
Fig. 4. Cathepsin S mRNA expression in RA A.
Cathepsin S mRNA expression in PBMCs of patients
with active RA (n=
19) and controls (n=
14) quantified by RT-qPCR. B. Expression analysis of
cathepsin S mRNA levels at synovial biopsies derived
from the RNA sequencing dataset GSE89408. Aligned
RNA-seq. data were downloaded from Gene
Expression Omnibus. C. Scatterplot showing corre-
lation of individual cathepsin S mRNA levels with
RNA editing rate in active RA PBMCs. D. Scatterplot
showing correlation of ADAR1 and cathepsin S
mRNA levels at synovial tissue of RA patients from
RNA-seq. dataset GSE89408; values are shown after
logarithmic transformation. Lines in the scatter-plots
represent mean ± SEM. P-values were produced by
Mann-Whitney U test or Spearman's rank test/
Pearson's test, respectively. Est. RA: established
rheumatoid arthritis (> 1 year disease duration).
Fig. 5. Proposed mechanism: Increased Alu A-to-I RNA editing fuels inflammatory gene expression in RA through post-transcriptional regulation of RNA metabolism.
Synovial or systemic inflammation induces the expression of the pro-inflammatory inducible ADAR1p150 isoform and consequently A-to-I RNA editing of Alu
elements. Increased Alu RNA editing may fuel inflammation by controlling the expression of inflammatory mediators through post-transcriptional HuR-dependent
mRNA stability/processing. Certain items on this figure have been adapted from Servier Medical Art by Servier (https://smart.servier.com – licensed under Creative
Commons Attribution 3.0 Unported License). p110: ADAR1p110, p150: ADAR1p150, HuR: human antigen R, TRAFs: TNF receptor-associated factors.
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treatment was able to decrease RNA editing levels in our patients. To
the best of our knowledge this is the first report showing the effect of
anti-inflammatory treatment on RNA editing levels in association with
clinical response. Whether RNA editing is a predictive biomarker of
clinical response and/or involved in the response to therapy remains to
be investigated in future studies.
Alu RNA editing can control various aspects of RNA metabolism
including splicing and mRNA stability, which can ultimately affect
expression levels of edited genes [10,12,47,48]. One of the major me-
chanisms leading to increased mRNA stability is the binding of the
stabilizing RNA-binding protein HuR to its target motifs TTTTG, TTTTT
and ATTTA located within the Alu elements [47,49]. Therefore, we also
checked whether increased RNA editing observed in active RA patients
led to aberrant gene expression, serving probably as an additional,
primate-specific regulatory mechanism at the post-transcriptional level.
Towards this goal, we used as exemplar the well-established ADAR1-
target cathepsin S [14]. Cathepsin S belongs to the family of lysosomal
cysteine proteases, which are critically involved in antigen presentation
and immune response [50]. In mice, knockout of cathepsin S prevents
collagen-induced arthritis [18], whereas increased circulating cathepsin
S protein levels have also been detected in RA patients [20]. Moreover,
cathepsin S may contribute to autoantibody production since it speci-
fically mediates degradation of the invariant chain Ii, thereby pro-
moting MHC-II antigen binding [15,16]. Previous studies have shown a
significant upregulation of cathepsin S in RA synovial fluid [19], sug-
gesting a role in synovial inflammation by its elastolytic properties and/
or by enhancing antigen presentation and autoantibody production.
Our findings show a significant increase of cathepsin S both at the
synovium and PBMCs of patients with RA which is significantly asso-
ciated with the expression of ADAR1 and especially of ADAR1p150, as
well as with the individual RNA editing rate of the adenosines located
within the AluSx+ of cathepsin S 3′ UTR. These associations imply that
the disruption of AluSx+ double-stranded RNA structure to a more
single-stranded one by A-to-I RNA editing reveals the HuR target-se-
quences enabling the single-strand RNA-binding protein HuR to bind to
its target cathepsin S, thus increasing its mRNA stability and expression,
as previously evidenced in a series of mechanistic studies [14]. Of in-
terest, cathepsin S is only one of the many edited Alu-enriched genes,
e.g. TRAFs, whose expression was found to be associated with ADAR1
in a large cohort of RA patients, suggesting that our proposed me-
chanism (Fig. 5) may be applicable to a large number of pro-in-
flammatory genes in RA or other inflammatory diseases. Further studies
are warranted to evaluate the role of A-to-I RNA editing in tran-
scriptome metabolism and cellular function in RA.
5. Conclusions
To conclude, our data reveal a previously unrecognized dynamic
regulation of Alu A-to-I RNA editing in RA that underpins therapeutic
response and fuels inflammatory gene expression. The pro-in-
flammatory inducible ADAR1p150 isoform acts as a transcriptome-wide
regulator of human-specific Alu-enriched inflammatory gene expression
and, thus, may comprise an interesting predictive biomarker and a
potential therapeutic target in patients with chronic inflammatory
(auto)immune-mediated diseases, as supported by recent promising
results in preclinical cancer models [51,52].
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